已收盤 11-20 16:00:00 美东时间
-0.170
-3.96%
Amneal Pharmaceuticals' biosimilar Adcomfo (omalizumab), developed as a biosimilar to XOLAIR, has received European Commission marketing authorization, following UK MHRA approval in March 2026. Adcomfo is approved for treating severe persistent allergic asthma, chronic rhinosinusitis with nasal polyps, and chronic spontaneous urticaria. Clinical studies demonstrated biosimilarity to the reference product, with comparable efficacy and safety. The ...
11-17 21:05
Alvotech shares are trading lower after the company reported worse-than-expected Q3 financial results.
11-12 22:20
11月12日,ALVOW(ALVOW)收涨28.57%,报0.18美元,成交额335美元,市值1007.23万美元。 行情数据 • 开盘价:0.18美元 • 最...
11-12 09:02
Alvotech (NASDAQ:ALVO) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.07) by 228.57 percent. This is a 1050 percent decrease over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $111.600 million wh...
11-12 05:26
Alvotech (NASDAQ:ALVO) affirms FY2026 sales outlook from $650.000 million-$700.000 million to $650.000 million-$700.000 million vs $651.278 million estimate.
11-12 05:17
今日重点评级关注:花旗:维持Faeth Therapeutics"买入"评级,目标价从55美元升至60美元;HC Wainwright & Co.:维持Ocular Therapeutix"买入"评级,目标价从25美元升至28美元
11-11 10:50
Jefferies analyst Dennis Ding initiates coverage on Alvotech (NASDAQ:ALVO) with a Buy rating and announces Price Target of $9.
11-10 22:37
11月3日,ALVOW(ALVOW)收涨21.14%,报0.3美元,成交额104美元,市值1651.37万美元。 行情数据 • 开盘价:0.3美元 • 最高价...
11-03 08:49
Alvotech will release its financial results for the first nine months and third quarter of 2026 on November 11, after U.S. market close. A webcast with live Q&A will follow on November 12 at 08:00 ET. Registration links for the earnings call and Q&A are provided, along with access to presentation materials on alvotech.com/financials. Alvotech, a global biotech company specializing in biosimilar medicines, has five approved biosimilars and a pipel...
10-28 11:00
Alvotech and Advanz Pharma have submitted a European regulatory application for AVT29, a proposed biosimilar to Eylea® 8 mg (aflibercept 114.3 mg/mL), marking the first global submission for a biosimilar to this high-dose formulation. AVT29 is being submitted as a line extension to the existing marketing authorization for Mynzepli® (aflibercept 2 mg). The 8 mg formulation of aflibercept allows for extended treatment intervals, potentially reducin...
10-14 08:30